



Polymeric Nanoparticles for Cancer Treatment

Guest Editors:

Dr. Enrique Niza

Instituto Botánico,
Departamento de Ciencia y
Tecnología Agroforestal y
Genética, Universidad de
Castilla-La Mancha, Campus
Universitario s/n, 02071 Albacete,
Spain

Dr. Francisco J. Cimas

Oncología traslacional, Unidad
de Investigación del Complejo
Hospitalario Universitario de
Albacete, 02008 Albacete, Spain

Deadline for manuscript
submissions:

closed (31 March 2023)

Message from the Guest Editors

Dear Colleagues,

Currently, the use of nanotechnology as a promising tool in cancer treatment is becoming a reality. Polymers have emerged as one of the most important and versatile raw materials to obtain novel nanovehicles to treat different types of cancer. The easy modification of different functional groups and polymeric chains can provide many types of polymers with a wide range of solubilities, including stimulus-responsive polymers that can allow selective drug release in different microenvironments and also the incorporation of various biomolecules to obtain smart nanovehicles, improving the selectivity and efficiency of nanosystems.

The search for new polymers that can be approved by different regulatory agencies for use as a raw material to obtain new nanoparticles for cancer treatment is currently an important topic in nanomedicine. In addition, establishing new methods for polymeric nanoparticle formulation, the encapsulation of new drugs and the modification of nanoparticles with different biomolecules to achieve more selective cancer treatment is a necessity.

Dr. Enrique Niza

Dr. Francisco J. Cimas

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma